CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security of $745.93 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2026-06-27 was $390.25M, a 47.14% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2026-03-28 was $355.68M, a 138.08% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2025-12-27 was $207.82M, a 17.56% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayment of long-term debt, long-term lease obligation, and capital security for the quarter ending 2025-09-27 was $253.79M, a 23.01% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2025 was $1.35B, a 9.67% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2024 was $1.49B, a 75.39% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2023 was $851.68M, a 70.96% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayment of long-term debt, long-term lease obligation, and capital security for fiscal 2022 was $2.93B, a 53.02% decline from fiscal 2021.
| Period end | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 3 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 6 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 9 month | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security 12 month |
|---|---|---|---|---|
| 2026-06-27 | $390.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $745.93M 10-Q · filed 2026-08-05 | $953.74M derived: sum of 3 quarters · filed 2026-08-05 | $1.21B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $355.68M 10-Q · filed 2026-05-07 | $563.49M derived: sum of 2 quarters · filed 2026-05-07 | $817.29M derived: sum of 3 quarters · filed 2026-05-07 | $1.56B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | $207.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $461.61M derived: sum of 2 quarters · filed 2026-02-18 | $1.20B derived: sum of 3 quarters · filed 2026-08-05 | $1.35B 10-K · filed 2026-02-18 |
| 2025-09-27 | $253.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $992.11M derived: sum of 2 quarters · filed 2026-08-05 | $1.14B 10-Q · filed 2025-11-05 | $1.32B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $738.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $887.71M 10-Q · filed 2026-08-05 | $1.06B derived: sum of 3 quarters · filed 2026-08-05 | $1.39B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $149.39M 10-Q · filed 2026-05-07 | $326.17M derived: sum of 2 quarters · filed 2026-05-07 | $655.82M derived: sum of 3 quarters · filed 2026-05-07 | $1.35B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $176.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $506.43M derived: sum of 2 quarters · filed 2026-02-18 | $1.20B derived: sum of 3 quarters · filed 2026-02-18 | $1.49B 10-K · filed 2026-02-18 |
| 2024-09-28 | $329.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.02B derived: sum of 2 quarters · filed 2025-11-05 | $1.32B 10-Q · filed 2025-11-05 | $1.64B derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $694.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $987.34M 10-Q · filed 2025-08-06 | $1.31B derived: sum of 3 quarters · filed 2026-02-18 | $1.52B derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $292.48M 10-Q · filed 2025-05-07 | $613.25M derived: sum of 2 quarters · filed 2026-02-18 | $827.11M derived: sum of 3 quarters · filed 2026-02-18 | $986.83M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $320.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $534.63M derived: sum of 2 quarters · filed 2026-02-18 | $694.35M derived: sum of 3 quarters · filed 2026-02-18 | $851.68M 10-K · filed 2026-02-18 |
| 2023-09-30 | $213.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $373.58M derived: sum of 2 quarters · filed 2024-11-06 | $530.91M 10-Q · filed 2024-11-06 | $939.16M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | $159.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $317.05M 10-Q · filed 2024-08-07 | $725.30M derived: sum of 3 quarters · filed 2025-02-19 | $1.39B derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-04-01 | $157.33M 10-Q · filed 2024-05-09 | $565.58M derived: sum of 2 quarters · filed 2025-02-19 | $1.23B derived: sum of 3 quarters · filed 2025-02-19 | $2.14B derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $408.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $1.08B derived: sum of 2 quarters · filed 2025-02-19 | $1.98B derived: sum of 3 quarters · filed 2025-02-19 | $2.93B 10-K · filed 2025-02-19 |
| 2022-09-24 | $668.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.58B derived: sum of 2 quarters · filed 2023-11-08 | $2.52B 10-Q · filed 2023-11-08 | $3.58B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-25 | $908.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.86B 10-Q · filed 2023-08-09 | $2.91B derived: sum of 3 quarters · filed 2024-02-14 | $3.86B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-26 | $948.27M 10-Q · filed 2023-05-11 | $2.00B derived: sum of 2 quarters · filed 2024-02-14 | $2.95B derived: sum of 3 quarters · filed 2024-02-14 | $5.48B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-25 | $1.05B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $2.00B derived: sum of 2 quarters · filed 2024-02-14 | $4.53B derived: sum of 3 quarters · filed 2024-02-14 | $6.24B 10-K · filed 2024-02-14 |
| 2021-09-25 | $948.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $3.48B derived: sum of 2 quarters · filed 2022-11-02 | $5.19B 10-Q · filed 2022-11-02 | $6.07B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | $2.53B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $4.24B 10-Q · filed 2022-08-03 | $5.12B derived: sum of 3 quarters · filed 2023-02-22 | $5.40B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | $1.71B 10-Q · filed 2022-05-04 | $2.59B derived: sum of 2 quarters · filed 2023-02-22 | $2.87B derived: sum of 3 quarters · filed 2023-02-22 | $2.99B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | $879.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.16B derived: sum of 2 quarters · filed 2023-02-22 | $1.28B derived: sum of 3 quarters · filed 2023-02-22 | $2.20B 10-K · filed 2023-02-22 |
| 2020-09-26 | $275.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $395.85M derived: sum of 2 quarters · filed 2021-11-03 | $1.32B 10-Q · filed 2021-11-03 | $2.65B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | $120.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.05B 10-Q · filed 2021-08-04 | $2.37B derived: sum of 3 quarters · filed 2022-02-16 | $3.09B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | $925.11M 10-Q · filed 2021-05-04 | $2.25B derived: sum of 2 quarters · filed 2022-02-16 | $2.97B derived: sum of 3 quarters · filed 2022-02-16 | $3.69B derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | $1.33B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $2.05B derived: sum of 2 quarters · filed 2022-02-16 | $2.76B derived: sum of 3 quarters · filed 2022-02-16 | $3.12B 10-K · filed 2022-02-16 |
| 2019-09-28 | $721.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $1.44B derived: sum of 2 quarters · filed 2020-10-29 | $1.80B 10-Q · filed 2020-10-29 | $2.17B derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-29 | $716.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.08B 10-Q · filed 2020-08-05 | $1.44B derived: sum of 3 quarters · filed 2021-02-17 | $1.60B derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-30 | $360.66M 10-Q · filed 2020-05-07 | $728.86M derived: sum of 2 quarters · filed 2021-02-17 | $881.45M derived: sum of 3 quarters · filed 2021-02-17 | $1.46B derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-29 | $368.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $520.80M derived: sum of 2 quarters · filed 2021-02-17 | $1.10B derived: sum of 3 quarters · filed 2021-02-17 | $2.20B 10-K · filed 2021-02-17 |
| 2018-09-29 | $152.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $736.01M derived: sum of 2 quarters · filed 2019-11-06 | $1.83B 10-Q · filed 2019-11-06 | $1.90B derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-06-30 | $583.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $1.68B 10-Q · filed 2019-07-31 | $1.74B derived: sum of 3 quarters · filed 2020-02-11 | $1.80B derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-03-31 | $1.10B 10-Q · filed 2019-05-07 | $1.16B derived: sum of 2 quarters · filed 2020-02-11 | $1.22B derived: sum of 3 quarters · filed 2020-02-11 | $1.31B derived: sum of 4 quarters · filed 2020-02-11 |
| 2017-12-30 | $63.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | $122.46M derived: sum of 2 quarters · filed 2020-02-11 | $214.29M derived: sum of 3 quarters · filed 2020-02-11 | $372.44M 10-K · filed 2020-02-11 |
| 2017-09-30 | $59.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $151.12M derived: sum of 2 quarters · filed 2018-11-07 | $309.26M 10-Q · filed 2018-11-07 | $438.91M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-07-01 | $91.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $249.97M 10-Q · filed 2018-08-08 | $379.63M derived: sum of 3 quarters · filed 2019-02-13 | $531.40M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-04-01 | $158.14M 10-Q · filed 2018-05-10 | $287.79M derived: sum of 2 quarters · filed 2019-02-13 | $439.57M derived: sum of 3 quarters · filed 2019-02-13 | $765.37M derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $129.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $281.43M derived: sum of 2 quarters · filed 2019-02-13 | $607.23M derived: sum of 3 quarters · filed 2019-02-13 | $656.64M 10-K · filed 2019-02-13 |
| 2016-09-24 | $151.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $477.57M derived: sum of 2 quarters · filed 2017-11-09 | $526.98M 10-Q · filed 2017-11-09 | $553.27M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-25 | $325.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $375.21M 10-Q · filed 2017-08-09 | $401.49M derived: sum of 3 quarters · filed 2018-02-13 | |
| 2016-03-26 | $49.41M 10-Q · filed 2017-05-10 | $75.69M derived: sum of 2 quarters · filed 2018-02-13 | ||
| 2015-12-26 | $26.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $417.33M 10-K · filed 2018-02-13 | ||
| 2015-09-26 | $391.05M 10-Q · filed 2016-11-02 | |||
| 2014-12-27 | $194.54M 10-K · filed 2017-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |